Literature DB >> 26321202

Genome-wide RNA-Seq of Human Motor Neurons Implicates Selective ER Stress Activation in Spinal Muscular Atrophy.

Shi-Yan Ng1, Boon Seng Soh2, Natalia Rodriguez-Muela1, David G Hendrickson3, Feodor Price1, John L Rinn4, Lee L Rubin5.   

Abstract

Spinal muscular atrophy (SMA) is caused by mutations in the SMN1 gene. Because this gene is expressed ubiquitously, it remains poorly understood why motor neurons (MNs) are one of the most affected cell types. To address this question, we carried out RNA sequencing studies using fixed, antibody-labeled, and purified MNs produced from control and SMA patient-derived induced pluripotent stem cells (iPSCs). We found SMA-specific changes in MNs, including hyper-activation of the ER stress pathway. Functional studies demonstrated that inhibition of ER stress improves MN survival in vitro even in MNs expressing low SMN. In SMA mice, systemic delivery of an ER stress inhibitor that crosses the blood-brain barrier led to the preservation of spinal cord MNs. Therefore, our study implies that selective activation of ER stress underlies MN death in SMA. Moreover, the approach we have taken would be broadly applicable to the study of disease-prone human cells in heterogeneous cultures.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26321202      PMCID: PMC4839185          DOI: 10.1016/j.stem.2015.08.003

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  33 in total

1.  Intrinsic capacities of molecular sensors of the unfolded protein response to sense alternate forms of endoplasmic reticulum stress.

Authors:  Jenny B DuRose; Arvin B Tam; Maho Niwa
Journal:  Mol Biol Cell       Date:  2006-05-03       Impact factor: 4.138

2.  Early functional impairment of sensory-motor connectivity in a mouse model of spinal muscular atrophy.

Authors:  George Z Mentis; Dvir Blivis; Wenfang Liu; Estelle Drobac; Melissa E Crowder; Lingling Kong; Francisco J Alvarez; Charlotte J Sumner; Michael J O'Donovan
Journal:  Neuron       Date:  2011-02-10       Impact factor: 17.173

3.  A functionally characterized test set of human induced pluripotent stem cells.

Authors:  Gabriella L Boulting; Evangelos Kiskinis; Gist F Croft; Mackenzie W Amoroso; Derek H Oakley; Brian J Wainger; Damian J Williams; David J Kahler; Mariko Yamaki; Lance Davidow; Christopher T Rodolfa; John T Dimos; Shravani Mikkilineni; Amy B MacDermott; Clifford J Woolf; Christopher E Henderson; Hynek Wichterle; Kevin Eggan
Journal:  Nat Biotechnol       Date:  2011-02-03       Impact factor: 54.908

4.  Induced pluripotent stem cells from a spinal muscular atrophy patient.

Authors:  Allison D Ebert; Junying Yu; Ferrill F Rose; Virginia B Mattis; Christian L Lorson; James A Thomson; Clive N Svendsen
Journal:  Nature       Date:  2008-12-21       Impact factor: 49.962

Review 5.  Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?

Authors:  Arthur H M Burghes; Christine E Beattie
Journal:  Nat Rev Neurosci       Date:  2009-07-08       Impact factor: 34.870

6.  ERdj5 is required as a disulfide reductase for degradation of misfolded proteins in the ER.

Authors:  Ryo Ushioda; Jun Hoseki; Kazutaka Araki; Gregor Jansen; David Y Thomas; Kazuhiro Nagata
Journal:  Science       Date:  2008-07-25       Impact factor: 47.728

7.  Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA.

Authors:  Luigi Warren; Philip D Manos; Tim Ahfeldt; Yuin-Han Loh; Hu Li; Frank Lau; Wataru Ebina; Pankaj K Mandal; Zachary D Smith; Alexander Meissner; George Q Daley; Andrew S Brack; James J Collins; Chad Cowan; Thorsten M Schlaeger; Derrick J Rossi
Journal:  Cell Stem Cell       Date:  2010-09-30       Impact factor: 24.633

8.  Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN.

Authors:  Kevin D Foust; Xueyong Wang; Vicki L McGovern; Lyndsey Braun; Adam K Bevan; Amanda M Haidet; Thanh T Le; Pablo R Morales; Mark M Rich; Arthur H M Burghes; Brian K Kaspar
Journal:  Nat Biotechnol       Date:  2010-02-28       Impact factor: 68.164

9.  Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions.

Authors:  Déborah Tribouillard-Tanvier; Vincent Béringue; Nathalie Desban; Fabienne Gug; Stéphane Bach; Cécile Voisset; Hervé Galons; Hubert Laude; Didier Vilette; Marc Blondel
Journal:  PLoS One       Date:  2008-04-23       Impact factor: 3.240

10.  SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing.

Authors:  Zhenxi Zhang; Francesco Lotti; Kimberly Dittmar; Ihab Younis; Lili Wan; Mumtaz Kasim; Gideon Dreyfuss
Journal:  Cell       Date:  2008-05-16       Impact factor: 41.582

View more
  56 in total

1.  Quantitative proteomics identifies proteins that resist translational repression and become dysregulated in ALS-FUS.

Authors:  Desiree M Baron; Tyler Matheny; Yen-Chen Lin; John D Leszyk; Kevin Kenna; Katherine V Gall; David P Santos; Maeve Tischbein; Salome Funes; Lawrence J Hayward; Evangelos Kiskinis; John E Landers; Roy Parker; Scott A Shaffer; Daryl A Bosco
Journal:  Hum Mol Genet       Date:  2019-07-01       Impact factor: 6.150

2.  Abnormal Golgi morphology and decreased COPI function in cells with low levels of SMN.

Authors:  S K Custer; J N Foster; J W Astroski; E J Androphy
Journal:  Brain Res       Date:  2018-11-05       Impact factor: 3.252

3.  Hyperexcitability precedes motoneuron loss in the Smn2B/- mouse model of spinal muscular atrophy.

Authors:  K A Quinlan; E J Reedich; W D Arnold; A C Puritz; C F Cavarsan; C J Heckman; C J DiDonato
Journal:  J Neurophysiol       Date:  2019-07-31       Impact factor: 2.714

4.  A Docosahexaenoic Acid-Derived Pro-resolving Agent, Maresin 1, Protects Motor Neuron Cells Death.

Authors:  Kazuki Ohuchi; Yoko Ono; Mina Joho; Kazuhiro Tsuruma; Shiho Ogami; Shinsaku Yamane; Michinori Funato; Hideo Kaneko; Shinsuke Nakamura; Hideaki Hara; Masamitsu Shimazawa
Journal:  Neurochem Res       Date:  2018-05-24       Impact factor: 3.996

5.  The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy.

Authors:  Constantin d'Ydewalle; Daniel M Ramos; Noah J Pyles; Shi-Yan Ng; Mariusz Gorz; Celeste M Pilato; Karen Ling; Lingling Kong; Amanda J Ward; Lee L Rubin; Frank Rigo; C Frank Bennett; Charlotte J Sumner
Journal:  Neuron       Date:  2016-12-22       Impact factor: 17.173

6.  Single-Cell Analysis of SMN Reveals Its Broader Role in Neuromuscular Disease.

Authors:  Natalia Rodriguez-Muela; Nadia K Litterman; Erika M Norabuena; Jesse L Mull; Maria José Galazo; Chicheng Sun; Shi-Yan Ng; Nina R Makhortova; Andrew White; Maureen M Lynes; Wendy K Chung; Lance S Davidow; Jeffrey D Macklis; Lee L Rubin
Journal:  Cell Rep       Date:  2017-02-07       Impact factor: 9.423

7.  Converging Mechanisms of p53 Activation Drive Motor Neuron Degeneration in Spinal Muscular Atrophy.

Authors:  Christian M Simon; Ya Dai; Meaghan Van Alstyne; Charalampia Koutsioumpa; John G Pagiazitis; Joshua I Chalif; Xiaojian Wang; Joseph E Rabinowitz; Christopher E Henderson; Livio Pellizzoni; George Z Mentis
Journal:  Cell Rep       Date:  2017-12-26       Impact factor: 9.423

Review 8.  SMN - A chaperone for nuclear RNP social occasions?

Authors:  Amanda C Raimer; Kelsey M Gray; A Gregory Matera
Journal:  RNA Biol       Date:  2016-09-20       Impact factor: 4.652

Review 9.  Evaluating cell reprogramming, differentiation and conversion technologies in neuroscience.

Authors:  Jerome Mertens; Maria C Marchetto; Cedric Bardy; Fred H Gage
Journal:  Nat Rev Neurosci       Date:  2016-05-19       Impact factor: 34.870

10.  A Stem Cell Model of the Motor Circuit Uncouples Motor Neuron Death from Hyperexcitability Induced by SMN Deficiency.

Authors:  Christian M Simon; Anna M Janas; Francesco Lotti; Juan Carlos Tapia; Livio Pellizzoni; George Z Mentis
Journal:  Cell Rep       Date:  2016-07-21       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.